Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)

Robert Klamroth,1 Kingsley Hampton,2 Sonata Saulyte Trakymienė,3 Lars Korsholm,4 Manuel Carcao5 1Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany; 2Department of Cardiovascular Science, University of Sheffield, Sheffield, UK; 3Clinic...

Full description

Bibliographic Details
Main Authors:	Klamroth R, Hampton K, Saulyte Trakymienė S, Korsholm L, Carcao M
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-11-01
Series:	Patient Preference and Adherence
Subjects:	extended half-life factor viii prophylaxis surgery joint health
Online Access:	https://www.dovepress.com/illustrative-cases-from-the-pathfinder-clinical-trials-of-patients-wit-peer-reviewed-fulltext-article-PPA

Similar Items

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
by: Vashi P, et al.
Published: (2021-11-01)

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
by: Steven R. Lentz, et al.
Published: (2022-02-01)

Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
by: Ilaria Nichele, et al.
Published: (2024-04-01)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
by: Napolitano M, et al.
Published: (2021-01-01)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
by: Ezio Zanon
Published: (2023-08-01)

Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy
by: Federica Demma, et al.
Published: (2022-06-01)

Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
by: Wu R, et al.
Published: (2020-06-01)

Treatment With Efmoroctocog Alfa (Elocta®) in Hemophilia: A Case Series
by: Ezio Zanon, et al.
Published: (2020-10-01)

Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus
by: Antonio Coppola, et al.
Published: (2022-02-01)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
by: Wynn TT, et al.
Published: (2016-06-01)

Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study
by: Azusa Nagao, et al.
Published: (2024-12-01)

Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey
by: Eichler H, et al.
Published: (2023-11-01)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
by: Byung Suk Moon, et al.
Published: (2013-07-01)

Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective
by: Daniela Paola Roggeri, et al.
Published: (2020-06-01)

Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice
by: Andrey G. Sarafanov
Published: (2023-05-01)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A
by: Chowdary P, et al.
Published: (2016-09-01)

Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
by: Masahiro Takeyama, et al.
Published: (2020-10-01)

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
by: Mariasanta Napolitano, et al.
Published: (2019-11-01)

GlycoPEGylated recombinant factor IX for hemophilia B in context
by: Santagostino E, et al.
Published: (2018-09-01)

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
by: Kearney S, et al.
Published: (2019-04-01)

Platelet function and microvesicle generation in patients with hemophilia A
by: Antonia Melero‐Amor, et al.
Published: (2021-03-01)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
by: Saunya Dover, et al.
Published: (2020-02-01)

Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
by: Takedani H, et al.
Published: (2015-03-01)

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
by: Michael U. Callaghan, et al.
Published: (2022-08-01)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
by: Tine M.H.J. Goedhart, et al.
Published: (2022-01-01)

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
by: Midori Shima
Published: (2020-05-01)

Development of inhibitors in hemophilia A: An illustrated review
by: Letícia Lemos Jardim, et al.
Published: (2020-07-01)

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies
by: Yang R, et al.
Published: (2020-11-01)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
by: Renchi Yang, et al.
Published: (2022-02-01)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
by: Jerome Teitel, et al.
Published: (2021-02-01)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
by: Stacy E. Croteau, et al.
Published: (2020-02-01)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
by: Pratima Chowdary, et al.
Published: (2019-07-01)

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
by: Anthony K. Chan, et al.
Published: (2020-10-01)

Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX–Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective–Prospective Study
by: Antonio Coppola, et al.
Published: (2024-03-01)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
by: Karla Rener, et al.
Published: (2023-11-01)

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
by: Haowei (Linda) Sun, et al.
Published: (2021-10-01)

Clinical and Laboratory Approaches to Hemophilia A
by: Hassan Mansouritorghabeh
Published: (2015-05-01)

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
by: Davide Matino, et al.
Published: (2022-03-01)

Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data
by: Escobar MA, et al.
Published: (2019-07-01)

Convenience Comparison Study of Reconstitution Devices for the Blood Coagulation Factor VIII Products Rurioctocog Alfa Pegol and Antihemophilic Factor (Recombinant)
by: Ueda H, et al.
Published: (2020-12-01)